This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Analog (ADI) Buys Symeo, Boosts Radar Technology Offerings
by Zacks Equity Research
Analog Devices (ADI) recently acquires Symeo GmbH to bolster its offerings in radar technology.
Analog Devices Prices Senior Notes, Gets Moody's Baa1 Rating
by Zacks Equity Research
Analog Devices (ADI) prices an offering of $750 million of senior unsecured notes.
Amazon to Expand in India by Adding Original Regional Content
by Zacks Equity Research
Amazon.com (AMZN) is planning to expand its original regional content that will strengthen competitive position in Indian streaming market.
Cooper Companies (COO) Tops Q1 Earnings & Revenue Estimates
by Zacks Equity Research
Cooper Companies (COO) Q1 results gain from strength in CooperVision segment.
Genomic Health (GHDX) Q4 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Genomic Health's (GHDX) escalating operating expenses dent bottom line in Q4.
Market Rally Boosts Household Net Worth: 5 Top-Ranked Picks
by Nalak Das
Substantial increase in wealth could make many Americans more confident and lead them to spend more fueling economic growth.
Amazon Roundup: Streams Music in India, Buys Ring
by Sejuti Banerjea
Amazon (AMZN) has launched Prime Music in the crowded Indian music streaming market and also picked up smart doorbell maker Ring for a billion dollars.
Orthofix PhysioStim's FDA Nod and CE Mark Boosts Prospects
by Zacks Equity Research
Orthofix (OFIX) vouches for PhysioStim's efficiency, claiming the devices to lead the U.S. market of prescribed bone growth stimulators combined with spinal fusion stimulators.
Quest Diagnostics Long-Term View Solid, Reimbursement a Woe
by Zacks Equity Research
Quest Diagnostics' (DGX) upgraded long-term guidance based on its new and extended two-point strategy looks promising. However, it expresses resentment against the recent PAMA-related CMS proposal.
Veeva Systems Vault Clinical Platform to Aid Ora's Operations
by Zacks Equity Research
Veeva Systems' (VEEV) Vault Clinical Suite to be incorporated into Ora's system for improved patient outcome.
Haemonetics (HAE) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Haemonetics (HAE) upbeat on integration of NexSys PCS device. A raised EPS guidance buoys optimism.
CryoLife (CRY) Beats Earnings and Revenue Estimates in Q4
by Zacks Equity Research
CryoLife (CRY) gains on growth in all the product lines along with a strong performance in all the geographies in Q4.
Falling Earnings Estimates Signal Weakness Ahead for Expedia (EXPE)
by Zacks Equity Research
Expedia (EXPE) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
NuVasive Gains From International Business Amid Pricing Woes
by Zacks Equity Research
Sturdy performance of NuVasive's (NUVA) international business with more than 20% growth for the fifth consecutive quarter raises optimism among investors
Amazon CEO Tops Forbes Rich List, Shares Hit 52-Week High
by Zacks Equity Research
Amazon (AMZN) attains 52-week high on AWS strength and diversified presence. Meanwhile, CEO Jeff Bezos tops Forbes Rich List for the first time.
Amedisys (AMED) Strong on Buyouts & Solid Personal Care Unit
by Zacks Equity Research
Amedisys (AMED) forges ahead with buyouts to boost capacity and geographical presence.
Abbott Gets FDA Nod for Masters HP 15mm, Boosts Portfolio
by Zacks Equity Research
Abbott (ABT) adopts initiatives to strengthen the Structural Heart business within the Medical Device segment.
Allscripts (MDRX) Launches Avenel to Revamp EHR Platform
by Zacks Equity Research
Allscripts' (MDRX) innovation team comes up with a user-friendly application, Avenel, to aid patients and clinicians through EHR.
Chimerix Q4 Loss Narrower Than Expected, Revenues Exceed
by Zacks Equity Research
Chimerix (CMRX) makes progress in Q4 through advancement with lead product candidate, brincidofovir. Revenues decline from lower reimbursable expenses regarding BARDA developmental contract.
Boston Scientific Acquires EMcision, Boosts Endoscopy Unit
by Zacks Equity Research
Boston Scientific (BSX) adopts initiatives to strengthen the Endoscopy business.
Abaxis Banks on Strong Veterinary Business Amid Margin Woes
by Zacks Equity Research
Abaxis' (ABAX) strong performance in Veterinary consumables drives growth. Weak gross and operating margin scenario is a concern.
3 Reasons Why You Should Invest in athenahealth (ATHN) Stock
by Zacks Equity Research
athenahealth (ATHN) rides on solid fourth-quarter results and strong fundamentals.
Here's Why Teleflex Has Been Losing Ground Since Q4 Earnings
by Zacks Equity Research
Teleflex's (TFX) contracted Q4 adjusted operating margin is discouraging.
BioTelemetry (BEAT) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
BioTelemetry (BEAT) sees strong Q4 results, courtesy of solid acquisitions and promising performance by the MCT platform.
eBay's (EBAY) Marketplace is Expected to Do Well in 2018
by Zacks Equity Research
eBay (EBAY) is making all efforts to improve its Marketplace business.